Two-year disease-free survival from evaluable Phase 2 patients expected by the end of Q1 2028.Strasbourg, France, April 13, 2026, 8:00 a.m. CET – ...
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, todayannounced that its management team will meet institutional ...
Transgene and NEC Bio ink agreement to prepare the next steps of the development of TG4050 in head and neck cancer: Strasbourg, France Monday, April 6, 2026, 17:00 Hrs [IST] Trans ...
Transgene’s therapeutic vaccine candidate TG4001 has flunked a phase 2 solid tumor trial. But, while the prospect failed to improve progression-free survival (PFS), the French biotech is continuing to ...
Transgene and ProBioGen, a CDMO, inked a license agreement for ProBioGen’s AGE1.CR.pIX ® suspension cell line which will combine ProBioGen’s specific production technology with the manufacturing ...
Transgene’s updated analyst narrative keeps the fair value price target anchored at €1.10, indicating that the headline valuation marker is unchanged in the latest refresh. Bullish and bearish ...
What's Transgene Biotek Ltd share price today. Get Transgene Biotek Ltd latest news on BSE/NSE stock price live updates, Transgene Biotek Ltd financial results and overview, Transgene Biotek Ltd stock ...
Transgene’s Two Innovative Platforms Progressing Well - Financial Visibility Extended Until End 2023
STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, ...
TG4050 is an individualized immunotherapy based on an MVA viral vector incorporating neoantigens selected using NEC’s AI-enabled prediction platform. It is currently being evaluated in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results